1
|
Wang M, Huang Q, Ma R, Wang S, Li X, Hu Y, Zhu S, Zhang M, Huang Q. Construction of Mn doped Cu 7S 4 nanozymes for synergistic tumor therapy in NIR-I/II bio-windows. Colloids Surf B Biointerfaces 2024; 234:113689. [PMID: 38103429 DOI: 10.1016/j.colsurfb.2023.113689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2023] [Revised: 11/23/2023] [Accepted: 12/01/2023] [Indexed: 12/19/2023]
Abstract
In photothermal therapy (PTT) and chemodynamic therapy (CDT) of cancer, poor performance of nanoagents severely impaired the therapeutic effect of cancer. To solve the problem, we proposed and constructed a novel Mn doped Cu7S4 phothermal nanoagent both in the first near-infrared (NIR-I) and the second near- infrared (NIR-II) windows in this work, which exhibited high photothermal conversion efficiency of 40.3% at 808 nm (NIR-I window) and 33.4% at 1064 nm (NIR-II window), as well as outstanding pH-sensitive catalytic performance (peroxidase-like catalytic activity and Fenton-like catalytic activities). The as-prepared Mn doped Cu7S4 could be used to load chemotherapy drug doxorubicin (DOX) after modified by folic acid. Both in vitro and in vivo studies indicated that it could be used as nanoagent for chemodynamic therapy (CDT)/photothermal therapy (PTT)/ chemotherapy of cervical carcinoma. This study thus provided an NIR-I/NIR-II/pH responsive nanoagent for potential synergistic therapy of deep-seated tumors.
Collapse
Affiliation(s)
- Meng Wang
- Public Experimental Research Center, the Second Clinical Medical College, Medical Technology School of Xuzhou Medical University, Xuzhou city, Jiangsu 221004, China
| | - Qi Huang
- Public Experimental Research Center, the Second Clinical Medical College, Medical Technology School of Xuzhou Medical University, Xuzhou city, Jiangsu 221004, China; School of Life Sciences, Nursing, Medical Imaging and Pharmacy of Xuzhou Medical University, Xuzhou city, Jiangsu 221000, China
| | - Ruixin Ma
- Public Experimental Research Center, the Second Clinical Medical College, Medical Technology School of Xuzhou Medical University, Xuzhou city, Jiangsu 221004, China
| | - Shuozhe Wang
- School of Life Sciences, Nursing, Medical Imaging and Pharmacy of Xuzhou Medical University, Xuzhou city, Jiangsu 221000, China
| | - Xinxiu Li
- School of Life Sciences, Nursing, Medical Imaging and Pharmacy of Xuzhou Medical University, Xuzhou city, Jiangsu 221000, China
| | - Youhui Hu
- School of Life Sciences, Nursing, Medical Imaging and Pharmacy of Xuzhou Medical University, Xuzhou city, Jiangsu 221000, China
| | - Shunhua Zhu
- Public Experimental Research Center, the Second Clinical Medical College, Medical Technology School of Xuzhou Medical University, Xuzhou city, Jiangsu 221004, China
| | - Min Zhang
- Public Experimental Research Center, the Second Clinical Medical College, Medical Technology School of Xuzhou Medical University, Xuzhou city, Jiangsu 221004, China
| | - Qingli Huang
- Public Experimental Research Center, the Second Clinical Medical College, Medical Technology School of Xuzhou Medical University, Xuzhou city, Jiangsu 221004, China.
| |
Collapse
|
2
|
Xia X, Yang X, Huang W, Xia X, Yan D. Self-Assembled Nanomicelles of Affibody-Drug Conjugate with Excellent Therapeutic Property to Cure Ovary and Breast Cancers. Nanomicro Lett 2021; 14:33. [PMID: 34902075 PMCID: PMC8669081 DOI: 10.1007/s40820-021-00762-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/31/2021] [Accepted: 10/14/2021] [Indexed: 05/06/2023]
Abstract
Affibody molecules are small non-immunoglobulin affinity proteins, which can precisely target to some cancer cells with specific overexpressed molecular signatures. However, the relatively short in vivo half-life of them seriously limited their application in drug targeted delivery for cancer therapy. Here an amphiphilic affibody-drug conjugate is self-assembled into nanomicelles to prolong circulation time for targeted cancer therapy. As an example of the concept, the nanoagent was prepared through molecular self-assembly of the amphiphilic conjugate of ZHER2:342-Cys with auristatin E derivate, where the affibody used is capable of binding to the human epidermal growth factor receptor 2 (HER2). Such a nanodrug not only increased the blood circulation time, but also enhanced the tumor targeting capacity (abundant affibody arms on the nanoagent surface) and the drug accumulation in tumor. As a result, this affibody-based nanoagent showed excellent antitumor activity in vivo to HER2-positive ovary and breast tumor models, which nearly eradicated both small solid tumors (about 100 mm3) and large established tumors (exceed 500 mm3). The relative tumor proliferation inhibition ratio reaches 99.8% for both models.
Collapse
Affiliation(s)
- Xuelin Xia
- School of Chemistry and Chemical Engineering, Frontiers Science Center for Transformative Molecules, Shanghai Jiao Tong University, Shanghai, 200240, People's Republic of China
| | - Xiaoyuan Yang
- School of Chemistry and Chemical Engineering, Frontiers Science Center for Transformative Molecules, Shanghai Jiao Tong University, Shanghai, 200240, People's Republic of China
| | - Wei Huang
- School of Chemistry and Chemical Engineering, Frontiers Science Center for Transformative Molecules, Shanghai Jiao Tong University, Shanghai, 200240, People's Republic of China
| | - Xiaoxia Xia
- State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, People's Republic of China.
| | - Deyue Yan
- School of Chemistry and Chemical Engineering, Frontiers Science Center for Transformative Molecules, Shanghai Jiao Tong University, Shanghai, 200240, People's Republic of China.
| |
Collapse
|